Remepy’s Hybridopa™, a novel Hybrid Drug™ combining levodopa/carbidopa with DopApp™ digital therapy, delivered significant motor and non-motor improvements in a Phase IIa Parkinson’s study, advancing toward global Phase III development.
Written By: Farha Farheen, PharmD
Reviewed By: Pharmacally Editorial Team
Remepy reported positive Phase IIa results for Hybridopa™, a Hybrid Drug™ that combines immediate-release levodopa/carbidopa with DopApp™, a personalized app-based digital therapeutic for Parkinson’s disease. The randomized, double-blind, placebo-controlled study met its primary endpoint, showing statistically significant improvements in combined MDS-UPDRS Parts I, II, and III scores compared with levodopa therapy paired with a placebo digital application.
The findings, published in Brain Communications provide early clinical and mechanistic evidence supporting integrated drug-software therapies in neurodegenerative disease management.
Parkinson’s disease progressively impairs dopamine-producing neurons, causing tremor, rigidity, slowed movement, balance dysfunction, and a wide range of non-motor symptoms including depression, sleep disruption, and cognitive decline. Although levodopa remains the standard treatment, many patients require multidisciplinary interventions involving physical, cognitive, behavioral, speech, and rehabilitative therapy to optimize long-term outcomes.
Hybridopa integrates these interventions into adaptive digital protocols delivered at home through DopApp. The software continuously adjusts therapeutic activities based on patient engagement, performance, and clinical status, reinforcing the personalized aspect of treatment.
The three-week Phase IIa trial enrolled 41 patients aged 45 to 80 years receiving stable levodopa doses ranging from 150 mg to 1,500 mg daily. Participants received either Hybridopa or levodopa combined with a placebo digital application.
Patients treated with Hybridopa achieved a mean 9.7-point reduction in combined MDS-UPDRS Parts I+II+III scores versus a 1.95-point reduction in the control group, reaching statistical significance (p=0.0005). Investigators also reported that 90% of Hybridopa-treated participants achieved at least a five-point improvement in MDS-UPDRS scores.
Notably, these improvements emerged after only three weeks of treatment, although longer-term durability remains to be established in larger studies.
Functional MRI analyses, conducted as exploratory mechanistic assessments, showed strengthened connectivity within motor and limbic brain circuits associated with movement control and mood regulation. Researchers also observed that higher engagement with specific DopApp modules correlated with domain-specific clinical improvements, suggesting that personalized digital interaction contributed directly to therapeutic response.
The company did not disclose detailed adverse event findings in the announcement, though the study advanced Hybridopa into planned late-stage development.
Or Shoval, Co-CEO of Remepy, said the data validate the concept that adaptive digital protocols can amplify the clinical impact of standard dopaminergic therapy. The company plans to initiate a pivotal global Phase III trial later this year.
Remepy also positioned Hybridopa within the emerging drug-software combination category, as regulators continue developing frameworks for prescription digital therapeutics and software-integrated medicines. If successful in Phase III testing, Hybridopa could become one of the most advanced software-pharmaceutical combination therapies in Parkinson’s disease development.
Reference
About the Writer
Farha Farheen, PharmD (LinkedIn) is a pharmacy professional with a strong interest in pharmacovigilance and clinical research. She has completed her Doctor of Pharmacy (Pharm.D) along with her internship as a Clinical Pharmacist. She has hands-on experience in adverse drug reaction (ADR) reporting, safety data documentation, and pharmacovigilance workflows, and is proficient in using VigiFlow. She is also a patent holder for an antibacterial formulation enriched with bioactive substances, granted by the German Patent and Trademark Office.